Table 1.
Patient characteristics.
| Parameter | Overall | On early Sampling Day | On late Sampling Day |
|---|---|---|---|
| Number of patients, n (%) a | 31 (100) | 25 (81) | 11 (35) |
| Demographics | |||
| Sex, male, n (%) | 19 (61) | ||
| Age, median (IQR), years | 72 (55–81) | ||
| Body weight, median (IQR), kg | 64 (60–77) | ||
| Clinical scores | |||
| Sequential Organ Failure Assessment score, median (IQR), n | 6 (4–9) | 8 (6–10), 15 | 5 (3–6), 11 |
| Acute physiology and chronic health evaluation II score, median (IQR) | 18 (16–26) | ||
| Biochemical parameters | |||
| Serum creatinine, median (IQR), mg/dL, n | 0.86 (0.71–1.04) | 0.91 (0.71–1.15), 25 | 0.8 (0.71–0.87), 11 |
| Cockcroft–Gault equation, median (IQR), mL/min, n | 73 (54–102) | 71 (49–90), 25 | 87 (58–109), 11 |
| Serum albumin, median (IQR), g/L, n | 29.5 (26.7–31.7) | 29.5 (26.8–31.6), 25 | 29.6 (26.2–31.5), 11 |
| Total bilirubin, median (IQR), mg/dL, n | 0.8 (0.25–0.6) | 0.38 (0.26–0.57), 25 | 0.28 (0.24–0.68), 11 |
| Sampling | |||
| Unbound ceftriaxone pre-dose concentration ≥1 mg/L, n (%) | 26/32 (81) | 17/21 (81) | 9/11 (81.8) |
| Unbound ceftriaxone pre-dose concentration ≥4 mg/L, n (%) | 15/32 (47) | 10/21 (47.6) | 5/11 (45.5) |
a Five patients were sampled on both days. IQR: interquartile range, n: number of patients.